Real-world bleeding risk with ibrutinib

Print Friendly, PDF & Email


Ibrutinib (Imbruvica)
Photo courtesy of Janssen
The Bruton tyrosine kinase inhibitor ibrutinib has been linked to a 20-fold increased risk of major bleeding in blood cancer patients taking concomitant antiplatelet and anticoagulation therapy in a clinical setting. Caution should be used when weighing the risks and benefits of ibrutinib for patients already taking antiplatelet or... [Read Article]
Print Friendly, PDF & Email

Group releases new CLL guidelines

Print Friendly, PDF & Email


Vials of drugs
Photo by Bill Branson
Fludarabine, cyclophosphamide, and rituximab are recommended as initial therapy for fit patients with chronic lymphocytic leukemia (CLL) who do not have TP53 disruption, according to new guidelines from the British Society for Haematology. The guidelines update the 2012 recommendations on CLL to include “significant” developments in treatment. The... [Read Article]
Print Friendly, PDF & Email

Team recommends melanoma screening in CLL

Print Friendly, PDF & Email


Micrograph showing CLL
Patients with chronic lymphocytic leukemia (CLL) should be routinely monitored for melanoma, according to researchers. A study of 470 CLL patients showed they have a significantly higher risk of invasive melanoma than the general population. Most of the melanomas reported in this study were detected via routine surveillance, and most were discovered... [Read Article]
Print Friendly, PDF & Email

Transplant strategy not viable for aggressive B-NHL

Print Friendly, PDF & Email


HSCT preparation
Photo by Chad McNeeley
Transplant with radioimmunotherapy (RIT)-based conditioning is a viable treatment option for patients with indolent—but not aggressive—B-cell non-Hodgkin lymphomas (NHLs), according to researchers. Long-term follow-up data showed “excellent” outcomes in patients with indolent B-NHL who received conditioning with 90Y-ibritumomab tiuxetan plus fludarabine and low-dose total body irradiation (TBI) prior... [Read Article]
Print Friendly, PDF & Email

Group updates guidelines on CLL

Print Friendly, PDF & Email


Micrograph showing CLL
Recent advances in chronic lymphocytic leukemia (CLL) have prompted an update to the 2008 International Workshop in Chronic Lymphocytic Leukemia (iwCLL) consensus guidelines. The updated iwCLL guidelines include new information on genomic alterations, the use of clinical staging and prognostic markers/scores, response assessment, minimal residual disease (MRD), and viral diseases in... [Read Article]
Print Friendly, PDF & Email

Combo proves ‘beneficial’ for ‘unfit’ CLL patients

Print Friendly, PDF & Email


Valentin Goede, MD
Obinutuzumab plus chlorambucil (G-Clb) is a “valid and beneficial” frontline treatment option for “unfit” patients with chronic lymphocytic leukemia (CLL), according to a speaker at the 23rd Congress of the European Hematology Association (EHA). Final results from the CLL11 study have revealed additional benefits of G-Clb over rituximab plus chlorambucil (R-Clb) in... [Read Article]
Print Friendly, PDF & Email

Peripheral blood MRD correlates with treatment benefit in CLL

Print Friendly, PDF & Email


Poster session at ASCO 2018
©ASCO/Scott Morgan 2018
Minimal residual disease (MRD) kinetics confirms the high, durable MRD-negativity with venetoclax plus rituximab in relapsed/refractory chronic lymphocytic leukemia (CLL), according to a further examination of the phase 3 MURANO study. The new results show higher concordance in MRD-negativity between bone marrow and peripheral blood in patients... [Read Article]
Print Friendly, PDF & Email

Ibrutinib and venetoclax combo promising in frontline CLL

Print Friendly, PDF & Email


Attendees at ASCO 2018 Annual Meeting
Photo by © ASCO/Zach Boyden-Holmes 2018
Ibrutinib combined with venetoclax is showing promising clinical activity in the frontline treatment of patients with chronic lymphocytic leukemia (CLL), according to investigators for the CAPTIVATE study. In the first 30 patients, 77% of treatment-naïve patients had undetected minimal residual disease (MRD) in... [Read Article]
Print Friendly, PDF & Email

Older, cheaper drug formulation to remain available

Print Friendly, PDF & Email


Imbruvica (ibrutinib)
Photo courtesy of Janssen
The 140 mg capsules of Imbruvica® (ibrutinib) will remain on the market, according to Pharmacyclics LLC. Pharmacyclics (an AbbVie company) and Janssen had planned to discontinue the capsules after introducing a single-tablet formulation of Imbruvica earlier this year. However, the companies received negative feedback about the discontinuation... [Read Article]
Print Friendly, PDF & Email

Umbralisib has ‘distinct’ safety profile

Print Friendly, PDF & Email


Micrograph showing CLL
Phase 1 trial results suggest umbralisib, a PI3Kδ/CK1ε inhibitor, can be safe and active in patients with relapsed or refractory B-cell malignancies. Researchers said the safety profile of umbralisib “was distinct from that of other PI3Kδ inhibitors,” as it produced few immune-mediated adverse events (AEs). Umbralisib also produced an objective response... [Read Article]
Print Friendly, PDF & Email

FDA issues CRL for proposed biosimilar rituximab

Print Friendly, PDF & Email


Micrograph showing
follicular lymphoma
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) saying the agency cannot approve Sandoz’s proposed biosimilar rituximab. Sandoz submitted the biologics licensing application for the product, known as GP2013, in September 2017. The company was seeking approval for GP2013 to treat follicular... [Read Article]
Print Friendly, PDF & Email

Radioimmunoconjugate shows activity in NHL

Print Friendly, PDF & Email


Mantle cell lymphoma
The radioimmunoconjugate 177Lu-NNV003 has demonstrated activity against non-Hodgkin lymphomas (NHLs). Experiments showed that 177Lu-NNV003 can inhibit proliferation in mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and chronic lymphocytic leukemia (CLL) cell lines. 177Lu-NNV003 also exhibited an antitumor effect and prolonged survival in mouse models of MCL, DLBCL, and CLL.... [Read Article]
Print Friendly, PDF & Email